ABSTRACT: Background. The purpose of this study was to report associations between p16 status, clinicopathologic characteristics, and outcomes for head and neck squamous cell carcinoma of unknown primary (CUP). Methods. Specimens of squamous cell CUP were reanalyzed. Human papillomavirus (HPV) status was determined by p16 stain. A tissue microarray (TMA) was constructed to evaluate biomarkers potentially prognostic in head and neck squamous cell carcinoma (HNSCC). Results. A majority of the population (n 5 26; 74%) was p16 positive (1). Prognostic factors benefiting survival were p161 status (p < .0001), absence of macroscopic extracapsular extension (ECE; p 5 .004), younger age (p 5 .01), and higher grade (p 5 0.007). The prognostic implication of worse overall survival (OS) with macroscopic ECE (p 5 .009) remained significant when limited to patients who were p161 (p 5 .002). Exploratory TMA between unknown primary and controls suggested a biomolecular difference between squamous cell CUP and known-primary cancer. Conclusion. The majority of patients with squamous cell CUP were p161, indicative of HPV association. P16 staining and ECE seem to be the most prognostic features in squamous cell CUP.
INTRODUCTION
Head and neck squamous cell carcinoma of unknown primary (CUP) describes a clinical scenario in which gross neck adenopathy demonstrates squamous cell carcinoma but no primary tumor can be identified, despite pursuit of thorough history, physical examination, and both noninvasive and invasive investigations, including biopsies. 1 It currently accounts for 5% of new diagnoses of head and neck squamous cell carcinoma (HNSCC) (range, 1% to 15%), 1,2 although the incidence may be lower after the adoption of functional imaging to help direct biopsies. 3 Two theories have been advanced to explain squamous cell CUP: (1) the primary tumor spontaneously regresses as a result of an immune reaction 4 or (2) a subclinical primary cancer remains viable, but dormant, and therefore never becomes clinically significant. 5 Although the pathogenesis of squamous cell CUP is uncertain, numerous reports show 2 features of the disease. First, most primary tumors not detected on physical examination reside in the oropharynx. 6 Even when directed oropharyngeal biopsies are unrevealing, the most likely location of the primary tumor is still the oropharynx (sparing the hypopharynx and larynx with radiotherapy fields does not adversely affect the low rate of primary mucosal emergence). 7 Second, unknown primary cancer seems to have a favorable prognosis when compared with other cancers of the upper aerodigestive tract, when treated with a variety of different regimens. As a consequence, there is increasing enthusiasm for deintensification of treatment for squamous cell CUPs. 8 In multiple recent multi-institution prospective analyses, [9] [10] [11] [12] human papillomavirus (HPV) association was found to be the strongest independent determinant of progression-free survival and overall survival (OS) among patients with oropharyngeal cancer. Analysis of banked tumor specimens has demonstrated that HPV-associated oropharyngeal cancer has been present for decades, 13 although its incidence is increasing. 14 HPV-associated oropharyngeal cancer typically presents with a smaller primary tumor and greater nodal bulk than are encountered in patients with tumors caused by substance abuse. 4, 9, 11 HPV-associated oropharyngeal carcinoma seems to have a favorable prognosis when compared with HPV-negative oropharyngeal carcinoma. As a consequence, deintensification of HPV-associated oropharyngeal cancer treatment has been addressed in clinical trials (NCT01084083 Eastern Cooperative Oncology Group 1308 and NCT01302834 Radiation Therapy Oncology Group 1016). In view of the favorable prognosis and large nodal burden (by comparison to the primary), the possibility that squamous cell CUP represents a variant of HPV-associated oropharyngeal carcinoma has been entertained.
At Fox Chase Cancer Center, squamous cell CUP has typically been managed with neck dissection, followed by adjuvant radiotherapy for N2 to N3 disease. As a consequence, the institution has banked specimens of squamous cell CUP treated with initial resection. This article reports the association between squamous cell CUP and presence of p16 stain by immunohistochemical analysis (IHC), the method determined to be the best (and favored) surrogate for ascertaining HPV status. 9, 15 It includes detailed pathologic and clinical characteristics, long-term outcomes, and identification of a biomolecular signature for squamous cell CUP via tissue microarray (TMA).
MATERIALS AND METHODS
We queried the tumor registry and an institutional tumor bank for patients with a history of squamous cell CUP treated with neck dissection. The relevant medical records and specimens were reviewed in accordance with a Fox Chase Cancer Center Institutional Review Boardapproved protocol and the Health Insurance Portability and Accountability Act. The medical chart was abstracted for data regarding patient presentation and tumor burden at diagnosis. Hematoxylin-eosin-stained slides were again reviewed and reanalyzed for typical morphologic features, including but not limited to: the size of largest involved lymph node, number of involved lymph nodes, presence and extent of extracapsular extension (ECE), presence or absence of keratinization, and grade. High-resolution monochromatic digital images of the cytokeratin staining visualized with AF555, diamidinophenylindole (DAPI), and target staining with Cy5 were captured and saved for every histospot on the arrays. Tumor mask was created from the cytokeratin image of each histospot, representing areas of epithelial tumor. Histospots were excluded if the tumor mask represented <5% of the total histospot area. DAPI immunoreactivity defined the nuclear compartment. The cytoplasmic compartment was defined by the tumor mask with specific exclusion of the nuclear compartment. Before automatic analysis mages were visually inspected and cropped for unfavorable findings, such as being out of focus or with the presence of debris or damaged tissue, target expression was quantified by calculating Cy5 fluorescent signal intensity within each image pixel. An automated quantitative analysis (AQUA) score was generated by dividing the sum of target signals within the tumor mask. AQUA scores were normalized to the exposure time and bit depth at which the images were captured, allowing scores collected at different exposure times to be directly comparable.
Clinical characteristics were compared by p161 protein status using Fisher's exact tests and Wilcoxon rank sum tests, as appropriate. Differences in ECE status by p161 protein status were determined using Fisher's exact test. Hazard ratio estimates for ECE definitions were estimated using Cox proportional hazards regression for time to death from all causes. The Kaplan-Meier product-limit method estimated OS and cause-specific survival functions by p16 status and ECE status. Surviving patients were censored at their last available follow-up date. Differences in the curves were assessed using the log-rank test. Cox proportional hazards regression was used for inferences about the relationship of survival time to p16 status, adjusting for age at diagnosis. Statistical analyses were performed using SAS statistical software, version 9.2 (Cary, NC) and survival plots were generated using the open-source R software (www.r-project.org). Because of the exploratory nature of this analysis, a type I error of 5% was used and there was no correction for multiple testing. The collection, storage, and retrieval of data were all done in compliance with the hospital's institutional review board and the Health Insurance Portability and Accountability Act.
RESULTS
We identified a total of 39 cases of squamous cell CUP treated with neck dissection between 1990 and 2010, 35 of which had sufficient material available for pathologic analysis. The median follow-up was 60 months (range, 3.5-226 months). Cases were most commonly (71%) from the second half of the study period (2000-2010). All patients were staged with preoperative imaging and endoscopy with systematic biopsy performed in 97%. The majority of patients (83%) were men and most (57%) had a >10 pack-year smoking history. Most patients (63%) presented with cN2 disease and 23% presented with cN3 disease. Level II (74%) was the most commonly involved station.
Initial neck dissection was the most common treatment approach (n 5 31; 89%). The type of neck operation performed was determined by the extent of disease at the time of surgery, but dissection of levels I to V was customary. All but 1 patient (97%) treated with initial lymphadenectomy received adjuvant radiotherapy. Almost all of the samples (89%) manifested keratinization and a majority of the specimens (63%) were noted to have a component of necrosis. The unadjusted hazard ratio estimate for ECE with OS was influenced by the definition of "macroscopic ECE" (Table 1) . Pathologic nodal staging was: 20% N1, 14% N2a, 51% N2b, 9% yN2b, 3% N3, and 3% yN3. The typical indication for adjuvant radiation of an N1 neck was diagnosis by virtue of an excisional biopsy undertaken before arrival at our institution. In all cases, radiotherapy (RT) was delivered to the mucosal subsites and both sides of the neck. Median dose to the high-risk volume was 60 (range, 58-70) in an adjuvant setting and 65 (range, 50-70) with preoperative radiation. A total of 4 patients (2 of whom were treated preoperatively) received concurrent systemic therapy (11%). The median 5-year OS for the study cohort was 77% (95% confidence interval [CI], 56% to 88%) and cancer-specific survival (CSS) was 86% (95% CI, 70% to 98%; Figure 1 ). Failures were rare. One p161 patient developed a tonsil primary. There were no recurrences in the neck and 3 patients developed distant metastases.
Pathologic reanalysis of the tumor specimens demonstrated that a majority of samples (74%; n 5 26) stained positive for the p16 protein (p161). Patients who were p161 were more likely to be men (p 5 .03) and younger (median, 50 vs 66 years; p 5 .04) in comparison to patients who were p16 negative (-). In contrast, smoking history (p 5 .82), neck stage at presentation (p 5 0.36), and use of adjuvant therapy was not associated with p16 status (100% of patients who were p161 received RT, 89% of patients who were p16-received RT). Necrosis was present in 100% of p16-samples compared to 50% of p161 samples (p 5 .01). Any ECE was more common among HPV-negative patients, although this did not reach statistical significance (78% vs 46%; p 5 .13), and keratinization was common regardless of p16 status (88%). There was a statistically significant OS benefit for patients who were p161 (p < .0001). This benefit persisted after controlling for age (p 5 .01). The 5-year OS was 92% (95% CI, 70% to 98%) for patients who were p161 as compared to 30% (95%CI, 5% to 63%) for patients who were p16-. The 5-year CSS was 92% (95% CI, 70% to 98%) for patients who were p161 as compared to 60% (95% CI, 13% to 88%); this did not reach statistical significance (Figure 2 ) in our small sample (p 5 .09). Higher-grade cancer was found to have a better prognosis (p 5 .006), likely secondary to rare failures in poorly differentiated tumors, which were frequently p161 (82%). Given the known prognostic significance of ECE in a postoperative setting 16, 17 and the hypothesis that the degree of ECE may be significant, we graded all ECE as either microscopic or macroscopic and analyzed the significance of ECE as a function of p16 staining. Detailed pathologic measurement of degree of ECE (Table 1) demonstrated that a cutoff of 2 mm was the best determinant of "clinically significant" ECE. Survival was significantly better (p 5 .004) among patients without macroscopic ECE (Figure 3) . Macroscopic ECE was observed in 19% of p161 and 44% of p16-patients. Among p161 patients, macroscopic ECE was still associated (p 5 .002) with a difference in OS (Figure 4) .
Of the 35 patients comprising the study cohort, 26 were consented for TMA analysis: 21 were p161 and 5 were p16-. The protein expression levels of various biomarkers were analyzed in this TMA using advanced AQUA technology. AQUA uses antibodies and fluorescent stains as molecular identification of compartments to quantify biomarker expression in specific tissues or subcellular components. This approach combines fluorescent immunoassay sensitivity and dynamic range with the location information typically provided by traditional IHC. Quality staining of some biomarkers are shown in Figure 5 . It has been demonstrated that AQUA scores are directly proportional to the molecular unit area and protein concentration. 18 Statistically significant increases of nuclear p53, survivin, ERCC, and RRM1 levels were recorded in p16-samples as compared to p161 samples (Table 1) . By contrast, both cytoplasmic and nuclear levels of AuroraA, HER2, pAKT, PARP, pAuroraA, and PTEN were quite similar regardless of p16 IHC. The remaining evaluated biomarkers (EGFR, phosphorylated epidermal growth factor receptor [pEGFR], and MET) had small differences that did not reach statistical significance in our small group.
An exploratory analysis demonstrated a surprisingly different biomarker profile between samples of known p161 oropharyngeal carcinoma and unknown primary p161 carcinoma. Statistically significant differences in nuclear expression of PTEN, RRM1, pAKT, and HER2 were demonstrated in a relatively small set of tumors. A similar exploratory analysis between p16-CUP and p16-known HNSCC demonstrated a more similar staining pattern, with only EGFR and pEGFR demonstrating a difference approaching significance (Table 2) .
DISCUSSION
There is no standard treatment paradigm for head and neck squamous cell CUP. As a consequence, management of this disease is institution-specific and generally based upon single center retrospective series. The common loci of controversy include determination of which modalities should be used to afford the best chance for cure with lowest possible long-term toxicity. An important purpose of this study was better to understand patients with squamous cell CUP in the hope that it would permit more sophisticated choice of therapy.
Traditional RT volumes for unknown primary carcinoma targeted both sides of the neck, the nasopharynx, oropharynx, larynx, and hypopharynx. These fields, still recommended by the National Comprehensive Cancer Network for adjuvant therapy, 19 result in satisfactory mucosal control (with a primary tumor emergence rate essentially the same as that expected for a second primary cancer), but likely cause unnecessary toxicity. Because the most common site of an occult primary is the oropharynx, 6 some centers have removed the larynx and hypopharynx from the field (when the nodal disease is in level II or III) without a rise in the rate of development of mucosal primary tumors, 7 suggesting that this is a safe approach to limiting toxicity. Squamous cell CUP is uncommon, and prospective trials to address management questions have not been undertaken. In their absence, the standard at our institution has been to perform a comprehensive cervical lymphadenectomy, followed by radiation to both sides of the neck, the oropharynx, and the nasopharynx (generally radiated as a consequence of covering the ipsilateral retrostyloid space and retropharyngeal nodes).
During the past 20 years, three-fourths of squamous cell CUP at the Fox Chase Cancer Center has been HPV associated. The percentage of HPV-associated tumors was much higher in the most recent decade (1990-2000: 50% p161 vs 2000-2010: 84% p161). Despite the keratinizing character of the most such lesions (a feature uncommon among HPV-associated oropharyngeal cancers), squamous cell CUP today is overwhelmingly referable to HPV. 20 What radiation dose is necessary to assure mucosal control in the setting of primary cancers quite sensitive to nonsurgical therapy? Recent series demonstrate decreasing mucosal doses 7, 21, 22 (median 55 Gy) with low mucosal emergence rates (<10%), similar to that (3%) in this report. Even lower mucosal doses may warrant consideration for virus-associated squamous cell CUP, perhaps even sparing the mucosa entirely and relying instead on dose "fall off" from treatment of the neck using an intensity-modulated approach. 23 It would seem that either chemoradiation or neck dissection followed by postoperative radiation will suffice to treat most patients with N2 and N3 disease from squamous cell CUP. Radiation alone may permit singlemodality therapy for selected N2 patients. 24 Recent use of transoral surgical techniques 25, 26 suggests a majority of unknown primary cancer is in fact occult base of tongue cancer. Thus, it is reasonable to suspect that most unknown primary cases in this series (and others) are in fact small T1 base of tongue cancers. HPV-associated base of tongue cancer with N2 to N3 neck nodes is generally managed with primary chemoradiation. Although it is anticipated that outcomes with both combined-modality treatment techniques (primary chemoradiation vs neck dissection 1 adjuvant radiation) will have favorable success rates in the HPV-associated unknown primary population, it is unclear which treatment paradigm is "best." Regardless of the preferred treatment technique, the results of this experience and others suggest that a majority of patients stand to benefit little from the more costly and morbid trimodality therapy.
With an up-front neck dissection management technique, decisions regarding adjuvant chemoradiation are predicated on the pathology findings. Although not systematically reported, it seems that for squamous cell CUP most centers use the same indicators for chemoradiation used for traditional postoperative RT (this is the recommendation of the National Comprehensive Cancer Network 19 ). Our present series demonstrates conclusively that many cases of ECE are relatively small (47% of cases of ECE were <2 mm) and suggests that so-called "microscopic ECE" has a different risk profile that does not justify the use of adjuvant chemoradiation.
A series of treatment intensification protocols 9-12 have attributed prognostic significance to p16 protein expression as an indicator of HPV-associated cancers with better treatment response. The present analysis demonstrates a similarly significant OS benefit among patients who are p161 with squamous cell CUP. In addition, this small unknown primary series suggests that the degree of ECE is similarly significant; the survival difference between p161 patients with (n 5 12) and without any ECE (n 5 14) was not significant (80% vs 100%; p 5 .2), whereas the same comparison among patients with (n 5 5) and without (n 5 21) macroscopic ECE was Abbreviations: EGFR, epidermal growth factor receptor; pEGFR, phosphorylated epidermal growth factor receptor.
FIGURE 6. Typical treatment regimen for patients with head and neck squamous cell carcinoma of unknown primary (CUP).
significant (95% vs 40%; p 5 .0018). Hence, there is little justification for administration of concurrent chemoradiation on the basis of ECE alone. Based on our analysis, it would seem that only macroscopic ECE could potentially justify the added morbidity ( Figure 6 ). The 13 biomarkers that we studied comprise a novel panel potentially important for risk stratification in locally advanced head and neck cancer. With only rare treatment failure, it proved impossible to divide patients into different prognostic groups based upon their markers. Hence, analysis was restricted to comparisons of the biomarker profiles of squamous cell CUP as a function of p16 status and in comparison with controls.
We demonstrated a statistically significant increase in both p53 and survivin nuclear expression among p16-unknown primary cancers, similar to that in known primary oropharyngeal cancer. 27, 28 It has been hypothesized that the dramatic difference in response to nonsurgical therapy is, in part, a consequence of differential p53 expression, and it seems that a similar principle governs unknown primary cancer. Also similar to known primary cancers was the demonstration of significant nuclear ERCC1 overexpression in p16-squamous cell CUP. 29 By contrast, the expression of both EGFR and downstream EGFR biomarkers (pEGFR and pAKT) 30 was not significantly different, in contrast to previous reports that high EGFR is either a poor prognostic factor, or associated with p16-disease, or both. 31, 32 Like EGFR, c-MET expression, associated with a poor prognosis in oral tongue cancer (an anatomic site characterized as HPVnegative), 33 was not significant in our small sample. Using the 13 biomarker panel between patients who were p161 and p161 controls (in an attempt to determine whether or not the unknown primary tumors seemed to be the same disease as the known primary HPVassociated tumors) with a limited number of controls (n 5 3), a difference was observed among pAKT, PTEN, and RRM1. Coupled with the difference between EGFR staining in our unknown primary patients and prior EGFR staining in cancers of known primary, these findings raise the possibility that squamous cell CUP represents a different form of HPV-associated carcinoma that is highly responsive to therapy.
